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Abstract
Background: The PACE Plus trial was a multi-center, double-blinded, superiority randomized controlled trial (RCT)
conducted in patients from Dutch general practice to investigate the efficacy of paracetamol and NSAIDs in acute
non-specific low back pain (LBP). Because insufficient numbers of patients could be recruited (only four out of the
required 800 patients could be recruited over a period of 6 months), the trial was prematurely terminated in
February 2017, 6 months after the start of recruitment. This article aims to transparently communicate the
discontinuation of PACE Plus and to make recommendations for future studies.
Methods: General Practitioners (GPs) from 36 participating practices received a one-question survey in which they
were asked to give the three most important factors that in their opinion contributed to failure of patient recruitment.
Results: GPs of 33 out of 36 (92%) participating practices sent a response. A total of 81 factors were reported. These
have been categorized into patient factors (26 out of 81 comments, 32%), GP factors (39 out of 81 comments, 48%)
and research factors (16 out of 81 comments, 20%).
Discussion: Patient recruitment in the PACE Plus trial may have failed due to inefficient medication distribution,
recruitment of incident rather than prevalent cases, a design that was too complicated, adequate self-management of
LBP, patient expectations different from the trial’s scope and lack of time of participating GPs. Substantial differences in
design may explain why the preceding PACE trial did manage to successfully complete patient recruitment.
Conclusion: Although the PACE Plus trial was terminated as a result of insufficient patient inclusion, the research
questions addressed in this trial remain relevant but unanswered. We hope that lessons learned from the discontinuation
of PACE Plus and corresponding recommendations may be helpful in the design of upcoming research projects in LBP in
general practice.
Trial registration: Dutch Trial Registration NTR6089, registered September 14th 2016.
Background
The PACE Plus trial was conducted in Dutch general prac-
tice to investigate the efficacy of paracetamol and NSAIDs
in acute non-specific low back pain (LBP) [1]. The study
design was a multi-center, placebo-blinded, superiority ran-
domized controlled trial (RCT). The two main aims of this
RCT were to replicate the comparison between paraceta-
mol and placebo as done in the PACE trial [2–4] and to
compare the efficacy of paracetamol with diclofenac and
advice only. The study protocol was published [1] and was
prospectively registered (Dutch Trial Registration
NTR6089, registered September 14th 2016). The Erasmus
MC Medical Research and Ethics Committee (MREC) has
granted approval for the PACE Plus trial (NL54941.078.16).
In short, our intention was to recruit 800 patients with
acute LBP from Dutch general practices, who would be
randomized across four treatment groups (paracetamol,
diclofenac, placebo or advice only) and would be followed
for 12 weeks. Inclusion and exclusion criteria for patient
recruitment in the PACE Plus trial can be found in Table 1.
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From May 2016, General Practitioners (GPs) were re-
cruited for participation in the trial. Initially, GPs who had
experience with patient recruitment in studies conducted
by the Erasmus Medical Center (EMC) Department of
General Practice were approached for participation. As a
second step in the recruitment of GPs, local GPs from the
provinces of Zuid-Holland, Noord-Brabant and Zeeland
and GPs who were specializing in musculoskeletal disor-
ders at the EMC were approached for participation. Fi-
nally, GP residents in their last year of training were asked
to participate as part of their training program.
Recruitment of eligible patients for the PACE Plus trial
started in September 2016. During the first 10 weeks of
the inclusion period of the trial, a total of 79 GPs from
26 practices participated in the trial; GPs from 11 of
these practices (42%) had participated in other studies of
the EMC Department of General Practice. Twenty-two
patients were referred for participation in the trial by a
total number of 12 practices. Four out of these 22 pa-
tients (18%) could be included in the trial. Eighteen out
of 22 (82%) referred patients were excluded; nine pa-
tients did not meet inclusion criteria, nine patients de-
clined to participate in the trial after being informed by
a research assistant over the phone. Reasons why re-
ferred patients did not meet inclusion criteria are pre-
sented in Table 2. Shortly after inclusion, the first
included patient declined further participation and was
lost to follow-up.
In November 2016, the trial was temporarily suspended
due to insufficient patient recruitment and the ‘Advice
only’-group was removed from the design after approval
from the Medical Research and Ethics Committee
(MREC) of the Erasmus MC and the funding party
(ZonMw), because a majority of participating GPs re-
ported that their patients with LBP did not accept the 25%
chance of receiving no medication whatsoever. The ‘Ad-
vice only’-group was perceived by many patients as well as
participating GPs as doing nothing. As a result of the de-
sign modification, two of the four included patients were
censored from the trial because they had been randomized
to the ‘Advice-only group’.
After the design modification, a total of 96 GPs from 36
practices participated in the trial; GPs from 13 of these
practices (36%) had participated in other studies of the
EMC Department of General Practice. Nine more patients
were referred for participation in the trial by a total num-
ber of six practices. None of the nine patients could be in-
cluded in the trial; four patients did not meet inclusion
criteria and five patients declined participation after being
informed over the phone by a research assistant.
Because insufficient numbers of patients could be in-
cluded despite the study design modification, the PACE
Table 1 Inclusion and Exclusion criteria for patient recruitment in the PACE Plus trial
Inclusion criteria Exclusion criteria
• Age between 18 and 60 years;
• Low back pain of less than 6 weeks duration;
• Primary complaint of pain between the 12th rib and buttock crease;
• Experiencing a new episode of low back pain, preceded by a period
of at least 1 month without low back pain;
• Low back pain severe enough to cause at least moderate pain
(≥4 on 0–10 numerical rating scale (NRS)).
• Known or suspected serious spinal pathology;
• Currently taking recommended regular doses of analgesics, including
paracetamol or diclofenac;
• Spinal surgery within the preceding 6 months;
• Serious comorbidities preventing prescription of paracetamol or
diclofenac;
• Use of medication interacting with paracetamol or diclofenac;
• Known intolerance for paracetamol or diclofenac;
• Pregnancy or planning to become pregnant during the treatment period.
Table 2 Patient referral and inclusion and exclusion in the PACE Plus trial
Trial period Before design modification After design modification Total
Number of participating GPs (number of participating practices) 79 (26) 96 (36) 96 (36)
Referrals (number of referring practices) 22 (12) 9 (6) 31 (15)
Exclusions (% of referrals) 18 (82%) 9 (100%) 27 (87%)
Patient did not meet inclusion criteria 9 4 13
Intake of study medicines before inclusion 5 1 6
Pain score (NRS 0–10) < 3 1 1 2
Specific cause of low back pain 0 1 1
Age > 60 years 1 0 1
Comorbidity/co-medication with interaction 1 1 2
Insufficient knowledge of Dutch language 1 0 1
Patient declined to participate 9 5 14
Inclusions (% of referrals) 4 (18%) 0 (0%) 4 (13%)
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Plus trial was terminated in February 2017, approxi-
mately 6 months after the start of recruitment. To inves-
tigate the underlying reasons for termination of this
RCT, GPs from all participating practices were sent a
survey. This publication has two aims: firstly, to provide
transparent communication about our unsuccessful pa-
tient recruitment, including results from the GP survey
and secondly, to make recommendations for future re-
searchers in this field of study in order to avoid the
problems encountered in this trial.
Methods
After the PACE Plus trial was discontinued, a letter
explaining the trial had been terminated because of insuf-
ficient patient recruitment was sent to all local research
collaborators (one GP for each participating practice, n =
36). Attached to this letter was a form with 3 blank answer
boxes and a single question: “In your opinion, what are
the (3) most important reasons why patient recruitment
failed?”. GPs were requested to return their answer to this
question in a pre-paid envelope that was provided.
Reminders were sent 2 and 3 months after the original let-
ter to GPs who had not yet responded to the survey.
MS extracted all responses into Microsoft Excel 2010 as
individual reasons. BK, PL and MS created 3 reason
categories: patient factors (i.e. factors related to patient
expectations and coping mechanisms), GP factors (i.e. fac-
tors related to presentation of patients in clinical practice
and organization of care) and Research factors (i.e. factors
related to trial design and organization). PL and MS
categorized all reasons into one of these categories. MS
computed percentages using Microsoft Excel 2010 and
interpreted initial results. BK and PL checked these com-
putations and interpretation. For categories with a mini-
mum of 8 responses (10% of total reasons), BK and MS
selected quotes that represented the opinions of multiple
GPs for that specific category. Quotes were translated
from Dutch to English by BK and MS.
Results
Twenty-six out of 36 GPs responded to the survey after
the first letter (19 returned the original filled-out form by
post, seven sent an e-mail with their opinion). Six out of
the remaining 10 GPs responded after the first reminder
(four by post, two by e-mail). After a final reminder, one
of the remaining four GPs responded to the question by
e-mail. In total, 33 out of 36 practices (94%) sent a re-
sponse. Not all respondents sent back exactly three fac-
tors, this ranged from one to four factors per response.
Responses were usually formulated as short sentences. A
total of 81 factors were reported (Table 3). These have
been categorized into patient factors (26 out of 81 com-
ments, 32%), GP factors (39 out of 81 comments, 48%)
and research factors (16 out of 81 comments, 20%).
Most of the comments about patient factors stated that
patients had other expectations when seeking care for LBP
than participating in a trial (14 out of 26 comments). Exam-
ples of these expectations from the survey were patients
asking either for alternatives for paracetamol or for stronger
pain medication than NSAIDs and patients requesting fur-
ther diagnostics by x-ray. One GP wrote: “The study went
against expectations of patients and doctors. The idea not to
Table 3 Results of survey amongst 33 participating GPs
GP opinions on why recruitment failed in the PACE Plus trial Total number of comments (% of total comments)
1. Patient factors: 26 (32%)
1.1 Patient had other expectations when seeking care for low back pain 14
1.2 Patients were confident they could self-manage their low back pain 7
1.3 Patient declined participation 5
2. GP factors: 39 (48%)
2.1 Insufficient number of patients meeting criteria were seen in practice or spoken
to on the telephone
20
2.2 Lack of time or trial forgotten because of other tasks 14
2.3 The trial had just started or had not yet started in the practice 3
2.4 Not all employees of the practice were sufficiently informed about the trial 2
3. Research factors: 16 (20%)
3.1 Medication distribution procedure too complicated 7
3.2 Research question and design irrelevant for clinical practice 4
3.3 Inclusion and exclusion criteria too restrictive 2
3.4 Research logistics disturb usual clinical care 2
3.5 Problems in communication with research department 1
Total number of comments from 33 GPs: 81 (100%)
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take or prescribe pain medication when someone is in pain
requires abstract reasoning. GPs aren’t happy to dismiss
paracetamol, too much time was invested to promote the
usefulness of this drug. This means there is a lose-lose situ-
ation; both the patient and the GP lose in this trial (at least
from a superficial point of view)”. Other patient factors
mentioned by GPs were that patients felt confident they
could self-manage their LBPs (using validated online pa-
tient information such as the patient information website of
the Dutch College of General Practitioners (NHG) [5] or
using direct access to physiotherapy, seven out of 26 com-
ments) and patients declining participation in the trial dir-
ectly in the practice (five out of 26 comments).
Nearly a quarter of all comments mentioned insufficient
numbers of patients meeting the inclusion criteria for the
PACE Plus trial presenting in the practice or on the phone
(20 comments). The quote best capturing this stated: “I per-
sonally see few people in my practice that meet the inclusion
criteria. Age, duration of complaints, etcetera. The GP’s as-
sistant solves a lot of cases; those patients could otherwise
have participated in the trial”. Another reason that was
often stated was lack of time due to patient care and ad-
ministration tasks (14 comments). Several GPs mentioned
forgetting about the trial because of the high workload; one
respondent wrote: “It’s very hectic! I only remembered to ask
my patient to participate after he’d already left”. Other GP
factors considered organizational issues in the GP practices:
two GPs stated that not all employees in the practice were
sufficiently informed about the trial, three GPs had only just
or not yet started participating in the trial.
Research factors reported could be related to both study
design choices and trial organization by the research de-
partment. Apart from the GPs mentioning insufficient
numbers of patients presenting in their practice, two GPs
explicitly stated that inclusion and exclusion criteria were
too restrictive to be realistic. Seven GPs found the medica-
tion distribution procedure too complicated and the sub-
sequent time delay before the patient received medication
unacceptable. Four GPs believed the trial research ques-
tion was irrelevant for clinical practice. Two GPs stated
that the trial design caused disturbance of usual clinical
care. Finally, one GP mentioned that communication with
the research department was not clear enough.
Discussion
Termination of the PACE Plus trial may be attributable to
research logistics and design, patient related and GP re-
lated factors. We will discuss these factors considering the
survey described above as well as reflecting on design
choices made in this trial’s predecessor, the PACE trial,
which did manage to successfully recruit 1650 patients
with comparable complaints.
In retrospect, an important weakness in the logistics of
PACE Plus was the complicated medication distribution
procedure, as mentioned by several GPs in the survey.
Patients could only be randomized once informed con-
sent was signed and the baseline questionnaire had been
filled out; very often, patients could not find the time to
do this immediately after referral, which meant
randomization and preparation of a medication pack
would be delayed. As GP practices participating in the
trial were spread across three Dutch provinces, 24-h
postal delivery was used to get medication packs to par-
ticipants. In practice, this meant that patients who were
in pain had to wait at least 24 to 48 h before receiving
medication; in contrast, if patients declined to partici-
pate in the trial and asked their GP for a prescription,
they would usually be able to pick up pain medication at
their local pharmacy within an hour. Alternatively, pa-
tients could buy paracetamol and NSAIDs as over-the-
counter medication without a prescription. Although
our medication distribution procedure did fit within the
limitations of Dutch law on medical research in humans,
we have underestimated the potential for delay to arise
in practice, the discomfort this meant for the partici-
pants and the unfavorable position of the trial in com-
parison to conventional treatment options.
During the design phase of PACE Plus, an alternative
medication distribution procedure was considered. In this
scenario, GPs would be asked to inform patients about the
trial, collect informed consent, randomize patients and
give them a medication pack immediately. However, under
Dutch law on medical research in humans, this meant
medication packs would have to be stored in a locked,
temperature controlled environment, for which extra re-
cords would have to be kept by participating GPs. Al-
though this scenario more closely resembled clinical
practice and diminished delay, the procedure was
dismissed because it would ask a substantially larger in-
vestment of time of participating GPs (who were already
on a very tight schedule) and would require purchasing
special medication storage equipment for all participating
practices, for which trial budget did not allow.
Apart from logistics, alternative target populations were
also considered during design of the trial. We chose to re-
cruit patients with a new episode of acute LBP (incident
cases) as opposed to prevalent cases of acute LBP (less
than 6 weeks of pain) for two reasons. Firstly, our main
aim was to replicate the PACE trial, which used incident
cases. Secondly, many patients with prevalent LBP would
already be using recommended doses of paracetamol or
NSAIDs and would therefore be ineligible for participa-
tion in the trial. A more feasible alternative might have
been to recruit patients with chronic LBP, but this of
course would mean investigating a completely different re-
search question and a design with a much longer follow-
up period. Therefore, although more challenging than the
alternatives, recruitment of incident cases of acute LBP
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seemed the most appropriate choice considering the aim
of our trial. The discontinuation of this trial supports the
previous finding that recruiting incident cases during the
GP’s consultation is associated with a lower probability of
complete and timely patient recruitment [6]. For future
research, other designs such as an RCT embedded in a co-
hort of patients with recurrent LBP could be considered
as an alternative to recruitment of incident cases during
the first consultation.
Another design choice that may have impacted the
feasibility of this trial was the objective to both repeat
PACE and explore the alternatives to paracetamol in one
trial. Not only did this mean that double the number of
patients had to be recruited than when comparing just
paracetamol and placebo, it also meant that the trial was
more complicated to explain to both participating GPs
and eligible patients. In hindsight, it might have been
better to focus on one of our objectives and design the
trial accordingly.
In terms of patient factors, effective self-management of
LBP may have had an impact on patient recruitment. This
is supported by the fact that the most important reason
for exclusion during PACE Plus was patients already tak-
ing one of the study medicines; furthermore, several GPs
mentioned in the survey their patients were confident they
could self-manage their LBP. Several societal develop-
ments could have contributed to this improved self-
management. Firstly, since 2006, patients have access to
physiotherapy without referral from a GP, although re-
search suggests this does not influence the number of GP
visits [7]. Secondly, it was demonstrated that the introduc-
tion of a patient information website of the NHG [5] has
led to a decrease in healthcare usage of 12% [8]. Finally,
both paracetamol and NSAIDs are available without a
doctor’s prescription, as they are registered as over-the-
counter medications in the Netherlands.
In PACE Plus, 14 of 27 excluded patients declined to
participate in the trial. This is highly related to the com-
ments of GPs that patients had other expectations and
that patients declined participation. The trial did not
provide any new treatment or in fact, any intervention
that the patient could not obtain over-the-counter as
mentioned above; instead, it relied on altruism of pa-
tients to answer the research question. The reason why
patients declined to participate may have been because
the underlying problem and research question were not
considered relevant enough by many patients, as was
mentioned in the survey by four GPs. This may have
been avoided by discussing research ideas with a group
of acute low back pain patients and taking their specific
preferences and expectations for both treatments and
outcomes into consideration.
Lack of GP’s time was often mentioned as a factor affect-
ing patient recruitment. This statement appears to reflect
recent trends in increasing workload for Dutch GPs be-
cause of changes in the national health care system [9]. As
a result of this increasing workload, less time is available for
participating in clinical research, which affects the feasibility
of conducting clinical trials in general practice [10].
GPs participating in the PACE Plus trial reported a
lower incidence of acute LBP than was initially expected
based on incidence figures reported in the NHG practice
guideline [11]. This may have been because of Lasagna’s
law [6, 12, 13], the phenomenon that researchers overesti-
mate the number of available patients meeting inclusion
and exclusion criteria of a trial (originally formulated as
“the incidence of patient availability sharply decreases
when a clinical trial begins”).
Considering PACE Plus investigated a highly similar
patient group and similar interventions to the original
PACE trial, we looked into differences between the two
studies that may explain why PACE successfully com-
pleted patient recruitment while PACE Plus failed to do
so. Firstly, the total budget in the PACE trial was sub-
stantially higher than in PACE Plus, which meant that in
PACE, three fulltime research assistants could be
employed as opposed to 1.2 fulltime equivalent in PACE
Plus. Furthermore, both GP’s and participants could be
reimbursed for their time invested in the trial in PACE,
whereas there was no compensation in PACE Plus.
Table 4 Lessons learned from discontinuation of the PACE Plus trial and corresponding recommendations for future research
Lessons learned Recommendations for future research
• Even though treatment distribution follows legislation and works on
paper, they may have issues in practice that affect patients.
• Asking GPs to recruit incident cases during the first consultation seems
unlikely to be successful considering the current workload in general
practice.
• Attempting to answer several research questions at once not only
requires more patients but is also more complicated to explain to
GPs and potential participants.
• Interests and expectations of patients can collide with scientifically
interesting questions in practice.
• The number of available patients meeting inclusion criteria is easily
overestimated (Lasagna’s Law).
• Negative perception of trial treatment may influence participation of
both GPs and patients.
• Keep treatment distribution as simple as possible and provide an
attractive alternative to conventional therapy.
• Try to answer your research question in prevalent cases or use
alternative designs such as a trial within a cohort study. Take into
account reimbursement of GPs in grant application and budgeting
(especially if you do end up recruiting incident cases).
• Choose your most important research question and design your trial
to be as simple as possible.
• Before starting a trial, ask a patient panel for their preferences and
expectations of treatments and outcomes. Ask GPs if they know of
any reservations about treatments you consider using.
• Take Lasagna’s law into account when planning your trial.
• Consider conducting a pilot trial and taking part in Mandatory
Continuous Education.
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Other strategies used in PACE but omitted in PACE Plus
included conducting a pilot trial and rewarding partici-
pating GPs with Mandatory Continuing Education
(MCE) points. In PACE, a ‘novel’ treatment (modified
release paracetamol) was investigated that could poten-
tially have been added to conventional treatment
options, whereas in PACE Plus, two of the treatments
were somewhat controversial both for GPs and patients
(diclofenac and no medication); additionally, some GPs
feared losing paracetamol as a treatment option. Finally,
as opposed to the complex medication distribution pro-
cedure used in PACE Plus, medication was allowed to be
directly provided by the GP preventing delay in patients
commencing their pain relief medicine.
Conclusion
Although the PACE Plus trial was terminated as a result
of insufficient patient inclusion, the research questions ad-
dressed in this trial remain relevant but unanswered. This
is especially true in light of recent international LBP
guidelines [14–17], in which the use of any medication for
LBP is discouraged. Lessons learned from the discontinu-
ation of PACE Plus and corresponding recommendations
have been summarized in Table 4. We hope that these les-
sons and recommendations may be helpful in the design
of upcoming research projects in LBP in general practice.
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